Form D · Other Technology
Proteas Bioanalytics Inc.
Torrance, CA · CIK 0001831825
Offering snapshot reported Mar 13, 2023 · SEC filing
- Reported sold
- $365K Offering amount: $3M
- Investors reported
- 5 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 11, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 13, 2023 | Initial | $365,000 | No comparison | 5 | SEC filing |
| Nov 10, 2021 | Amendment | $1,420,000 | $1,055,000vs Nov 9, 2020 | 7 | SEC filing |
| Nov 9, 2020 | Initial | $365,000 | No comparison | 3 | SEC filing |
Offering details
- Securities
- Debt, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-475680
Source: Form D, filed Mar 13, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Valerie Darling | Director |
| Spiros Garbis | Director, Executive |
| Keith B. Hoffman | Director |
| Dimitrios Iliopoulos | Director |
| Antigoni Manousopoulou | Director |
Issuer details
Industry: Other Technology (See others in industry)
Address:
Biolabs At The Lundquist Institute 1124 W. Carson St., Mrl Building 3rd Fl
Torrance, CA, 90502
Torrance, CA, 90502